替罗非班治疗老年非ST段抬高急性冠脉综合征的临床研究

Tirofivan used in treatment of senile acute coronary syndrome with non-ST elevation

目的评价替罗非班治疗老年非ST段抬高急性冠状动脉综合征(NSTEACS)患者的有效性和安全性。方法将符合老年NSTEACS患者68例随机分为治疗组(n=34)和对照组(n=34),行药物保守治疗,治疗组在对照组常规治疗的基础上联合使用替罗非班。比较两组住院期间及出院后3个月内主要心血管事件(MACE)的发生率及出血发生率。结果治疗组随访3个月MACE发生率(14.7%)较对照组(35.3%)显著降低,两者差异有统计学意义(P<0.05)。出血发生率两组差异无统计学意义(P>0.05)。结论替罗非班治疗老年NSTEACS患者可减少心血管事件且安全性好。

Objective To review the curative effect and safety of tirofivan in the treatment of senile acute coronary syndrome with non-ST elevation.Methods The patients （n=68） with senile acute coronary syndrome with non-ST elevation were randomly divided into the treatment group （n=34） and control group （n=34） and given conservative treatment.On the base of conventional therapy like the control group,the treatment group was given tirofivan.The incidence rates of major adverse cardiac events （MACE） and hemorrhage were compared between two groups during hospitalization and within 3 months after discharging from hospital.Results The incidence rates of MACE was lower significantly in the treatment group （14.7%） than that in the control group （35.3%） after follow-up for 3 months and the difference between two groups was significant statistically （P0.05）.The incidence rate of hemorrhage had no significant difference between two groups （P0.05）.Conclusion Tirofivan can reduce major adverse cardiac events and is safe for the patients with senile acute coronary syndrome with non-ST elevation.